Newcourt Acquisition Corp. (NCAC) Closes Psyence Deal
by Marlena Haddad on 2024-01-25 at 6:14pm

Newcourt (NASDAQ:NCAC) has closed its combination with psychedelic medicine company Psyence (CSE:PSYG) and will begin trading on The Nasdaq under the new ticker symbol ticker symbol “PBM” on January 26.

Shareholders previously approved the combination during a special meeting held on January 18.

In connection with last week’s vote, shareholders opted to redeem 929,727 shares at a redemption price of approximately $11.51 per share, removing about $10.7 million from Newcourt’s trust and leaving it with 183,294 public shares outstanding and about $2.1 million in trust.

In connection with the combination, Psyence Biomed entered into a securities purchase agreement under which it will raise up to $10 million in funding through the issuance of up to four senior secured convertible notes with a US-based investment firm. The combined company intends to use the note financing to further its clinical trials conducted in Australia.

Psyence Biomed has partnered with the Australian-based research organization iNGENu to conduct its clinical trial in palliative care. Upon successful completion of the study, the combined company plans to conduct a multinational Phase III study.

The SPAC announced its deal with Psyence in January 2023. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.

Psyence Biomedical plans to use the funds from the deal to expedite its clinical trials and expand its market presence.


ADVISORS

  • Bayline Capital Partners Inc. is acting as capital markets advisor to Psyence.
  • WeirFoulds LLP is acting as Canadian legal advisor to Psyence.
  • Morgan, Lewis & Bockius LLP is acting as U.S. legal advisor to Psyence.
  • McDermott Will & Emery LLP is acting as U.S. legal advisor to Newcourt.
Recent Posts
by Nicholas Alan Clayton on 2024-11-22 at 12:44pm

Hudson I (NASDAQ:HUDA) has signed a definitive agreement to combine with EV maker Aiways Europe at an equity value of $410 million. Munich, Germany-headquartered Aiways Europe is developing a line of EV SUVs for the European market with support from an affiliate manufacturer in China. The combined company is expected to trade on the Nasdaq...

by Nicholas Alan Clayton on 2024-11-22 at 9:52am

The clearest theme for the changes to come under the incoming Trump administration is lower taxes domestically and trade barriers abroad. And, the election’s impacts on the investment climate have been broadly favorable to SPACs, but this policy-making direction could have detrimental impacts on SPAC deals themselves. That’s because international targets have made up an...

by Nicholas Alan Clayton on 2024-11-22 at 8:15am

At the SPAC of Dawn Activity has been picking up in SPACland after a sleepy start to the month, but the biggest news for the this corner of the market is not SPAC-specific. SEC Chair Gary Gensler announced his intention to resign on January 20. His resignation press release touted the $21 billion in penalties...

by Nicholas Alan Clayton on 2024-11-21 at 12:35pm

Deals and Amendments Arogo Capital (OTC:AOGO) has received notice that its merger target Ayurcann Holdings (CSE:AYUR) has terminated their business combination citing a breach on behalf of the SPAC. Ayurcann expects to be paid a $250,000 breakup free from Arogo. News and Rumors PR: Smart TV firm Innovid (NYSE:CTV), which combined with ION 2 in...

by Nicholas Alan Clayton on 2024-11-21 at 8:31am

At the SPAC of Dawn Wednesday night saw two more SPACs price their IPOs, which means November’s eight listings will now eclipse October’s haul of seven and the five IPOs of September. Amid this accelerating momentum, a new name could soon be seen on a number of new SPACs. EF Hutton rebranded to D. Boral...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved